Smart Vitamins raises €2.1 million to fund the first clinical trial of its flu prevention therapy

The company Smart Vitamins, a spin-off of the University of Santiago de Compostela, has raised 2.1 million euros to finance the first clinical trial of its SV B – I therapy, which, in preclinical experiments with rodents, has managed to prevent the development of influenza in 100% of cases after being infected with the influenza virus.

This is a therapy that has been developed with the Smart Delivery of Nutrients Technology (SDN) platform, created by the laboratory of María José Alonso,scientific director and co-founder of Smart Vitamins and a pioneer in the field of nanomedicine,which allows the precise administration and distribution of drugs, vitamins and other essential nutrients, obtaining therapeutic effects through different administration routes, one of the main ones being the topical route.

“This highly versatile technological platform, protected by a family of international patents, has applications in the pharmaceutical, nutraceutical and cosmetic markets, and has allowed us to create the SV B – I therapy, which has obtained very significant results in the efficacy trials carried out on rodents and we hope that it will also achieve them in the efficacy clinical trial with humans, which we will begin in early 2026 in the United Kingdom,” explains Alfredo Bermúdez de Castro Franco, CEO and co-founder of Smart Vitamins.

The company, which conducted all preclinical research for its flu prevention therapy with its own resources, has raised €2.1 million for its first clinical trial through high-value strategic investors such as Vicente Durán, president of the Medpoint group; Antonio Parente, president of GP Pharm and BCN Peptides; Roberto Conde, founder of Nutrición Médica Cantabria Labs; Santiago Domínguez, partner at Sémola Ventures and president of SCiY (a division of Bruker Biospin)5; José Luis del Río, CEO of Arcano; and Roberto Pomares, managing partner of Addleshaw Goddard Spain, among others.

“We have seen over more than two years of collaboration, the enormous potential of the technology developed by Smart Vitamins, in the field of respiratory infections, autoimmune diseases and ophthalmology. For this reason we wanted to participate in the company by leading its first round of financing, with the aim of achieving the commercialization of its therapy to prevent respiratory infections and advancing its developments in the dermatological field” says Vicente Durán, president of the Medpoint group.

Thanks to this round of financing, Smart Vitamins will also be able to validate the efficacy of its therapy on other respiratory viruses such as Sars Cov 2 and Respiratory Syncytial Virus, as well as expand its patent portfolio.

"With this round of financing, fully backed by high-value strategic investors, we have brought together all the elements that make up the value chain necessary to bring our SV B – I therapy to market: we have the necessary financing to conduct the first clinical trial and we have the global manufacturing and distribution capabilities for the therapy. Furthermore, this round will allow us to accelerate the market translation of our developments in clinical and cosmetic dermatology, and ophthalmology," emphasizes the company's CEO.